Search research articles
Contact Us
Filters
Showing results (31-40 of 33) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 33 results.
Journal of Surgical Oncology
|
January 6, 2015
Developing a prognostic model for localized Ewing sarcoma family of tumors: A single institutional experience of 224 cases treated with uniform chemotherapy protocol
Bivas Biswas, S Rastogi, S A Khan, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
June 13, 2014
Hypoalbuminaemia is an independent predictor of poor outcome in metastatic Ewing's sarcoma family of tumours: a single institutional experience of 150 cases treated with uniform chemotherapy protocol
B Biswas, S Rastogi, S A Khan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2025
A Phase II, Randomized, open-label study to evaluate low-dose Pembrolizumab plus Chemotherapy vs Chemotherapy as Neoadjuvant Therapy for localized Triple Negative Breast Cancer (TNBC). [PLANeT Trial - Pembrolizumab Low Dose in Addition to NACT in TNBC]
A Arora, H Bhaskarane, G Tansir, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 33) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 33 results.
Journal of Surgical Oncology
|
January 6, 2015
Developing a prognostic model for localized Ewing sarcoma family of tumors: A single institutional experience of 224 cases treated with uniform chemotherapy protocol
Bivas Biswas, S Rastogi, S A Khan, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
June 13, 2014
Hypoalbuminaemia is an independent predictor of poor outcome in metastatic Ewing's sarcoma family of tumours: a single institutional experience of 150 cases treated with uniform chemotherapy protocol
B Biswas, S Rastogi, S A Khan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 24, 2025
A Phase II, Randomized, open-label study to evaluate low-dose Pembrolizumab plus Chemotherapy vs Chemotherapy as Neoadjuvant Therapy for localized Triple Negative Breast Cancer (TNBC). [PLANeT Trial - Pembrolizumab Low Dose in Addition to NACT in TNBC]
A Arora, H Bhaskarane, G Tansir, et al.
Page
of 4